SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers
- 1Memorial Sloan Kettering Cancer Center
Abstract
Approximately 10% of bladder, upper urinary tract, and endometrial cancers harbor deleterious somatic alterations in nucleotide excision repair (NER) pathway genes. Although platinum-based chemotherapy is the standard treatment for NER-deficient tumors, its utility is limited by nephrotoxicity, motivating alternative strategies that avoid direct DNA targeting. Here, we employed a genome-wide CRISPR-Cas9 screen to identify synthetic lethal vulnerabilities in NER-deficient cancer cells. An ERCC4-null RT112/84 bladder cancer cell line was generated and validated by Sanger sequencing and Western blotting, and functional NER deficiency was confirmed using a host cell reactivation assay. Parallel screens in ERCC4-deficient and isogenic wild-type cells. nominated SLC25A28 as the top-ranked synthetic lethal candidate in ERCC4-deficient cells, an interaction further supported by DepMap dependency. Clonogenic assays confirmed that loss of SLC25A28 selectively impaired cell viability in cells deficient for ERCC2, ERCC3, ERCC4, or ERCC5 and inducible knockout selectively suppressed ERCC4-deficient xenograft growth in-vivo. Mechanistically, RNA sequencing followed by gene set enrichment analysis revealed enrichment of oxidative stress-related pathways, including cellular responses to reactive oxygen species (ROS) and DNA damage signatures, upon SLC25A28 loss. These transcriptional changes are consistent with increased oxidative stress and DNA damage, placing heightened demand on NER-mediated repair. Direct measurement confirmed increased intracellular ROS. Collectively, our nominates SLC25A28 as a previously unrecognized synthetic lethal vulnerability in NER-deficient cancers and implicate mitochondrial iron homeostasis as a candidate metabolic dependency that may be targeted independently of platinum-based chemotherapy.
Related
- FANCM restrains structural genome evolution and defines a synthetic lethal dependency in BRCA1-deficient breast cancer
- HSV-1 UL42 and UL47 hijack cellular nucleotide synthetic enzyme CAD to promote lytic replication
- Synthetic lethal screens reveal p300/CBP as a vulnerability for GNAQ-driven uveal melanomas
- Cumate-inducible models of MYC-driven neuroblastoma identify mitoribosomal synthetic lethality as a precision oncology vulnerability in MYC(N)-amplified tumors
- Prognostic significance of SLC25A28 and its associations with mitochondrial metabolism and immune features in glioma
BibTeX
@misc{yang2026slc25a28,
title = {{SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers}},
author = {N. Yang and L. Hoeg and X. Bai and S. Gao and E. de Stanchina and D. Solit and S. Topka and S. Belhadj and J. Carrot-Zhang and G. Iyer and D. Durocher and K. W. Mouw and V. JOSEPH and K. Offit and S. Lipkin},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.05.756638},
url = {https://www.biorxiv.org/content/10.64898/2026.10.05.756638v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers
AU - N. Yang
AU - L. Hoeg
AU - X. Bai
AU - S. Gao
AU - E. de Stanchina
AU - D. Solit
AU - S. Topka
AU - S. Belhadj
AU - J. Carrot-Zhang
AU - G. Iyer
AU - D. Durocher
AU - K. W. Mouw
AU - V. JOSEPH
AU - K. Offit
AU - S. Lipkin
PY - 2026
DA - 2026/10/05
PB - bioRxiv
DO - 10.64898/2026.10.05.756638
UR - https://www.biorxiv.org/content/10.64898/2026.10.05.756638v1
AB - Approximately 10% of bladder, upper urinary tract, and endometrial cancers harbor deleterious somatic alterations in nucleotide excision repair (NER) pathway genes. Although platinum-based chemotherapy is the standard treatment for NER-deficient tumors, its utility is limited by nephrotoxicity, motivating alternative strategies that avoid direct DNA targeting. Here, we employed a genome-wide CRISPR-Cas9 screen to identify synthetic lethal vulnerabilities in NER-deficient cancer cells. An ERCC4-null RT112/84 bladder cancer cell line was generated and validated by Sanger sequencing and Western blotting, and functional NER deficiency was confirmed using a host cell reactivation assay. Parallel screens in ERCC4-deficient and isogenic wild-type cells. nominated SLC25A28 as the top-ranked synthetic lethal candidate in ERCC4-deficient cells, an interaction further supported by DepMap dependency. Clonogenic assays confirmed that loss of SLC25A28 selectively impaired cell viability in cells deficient for ERCC2, ERCC3, ERCC4, or ERCC5 and inducible knockout selectively suppressed ERCC4-deficient xenograft growth in-vivo. Mechanistically, RNA sequencing followed by gene set enrichment analysis revealed enrichment of oxidative stress-related pathways, including cellular responses to reactive oxygen species (ROS) and DNA damage signatures, upon SLC25A28 loss. These transcriptional changes are consistent with increased oxidative stress and DNA damage, placing heightened demand on NER-mediated repair. Direct measurement confirmed increased intracellular ROS. Collectively, our nominates SLC25A28 as a previously unrecognized synthetic lethal vulnerability in NER-deficient cancers and implicate mitochondrial iron homeostasis as a candidate metabolic dependency that may be targeted independently of platinum-based chemotherapy.
ER -